BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26930181)

  • 1. Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
    Hinshaw L; Schiavon M; Dadlani V; Mallad A; Dalla Man C; Bharucha A; Basu R; Geske JR; Carter RE; Cobelli C; Basu A; Kudva YC
    J Clin Endocrinol Metab; 2016 May; 101(5):1954-62. PubMed ID: 26930181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
    Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
    Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function.
    Hinshaw L; Schiavon M; Mallad A; Man CD; Basu R; Bharucha AE; Cobelli C; Carter RE; Basu A; Kudva YC
    Am J Physiol Endocrinol Metab; 2014 Sep; 307(6):E494-502. PubMed ID: 25074985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
    Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
    Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
    Sherr JL; Patel NS; Michaud CI; Palau-Collazo MM; Van Name MA; Tamborlane WV; Cengiz E; Carria LR; Tichy EM; Weinzimer SA
    Diabetes Care; 2016 Jul; 39(7):1127-34. PubMed ID: 27208332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
    Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
    Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
    Galderisi A; Sherr J; VanName M; Carria L; Zgorski M; Tichy E; Weyman K; Cengiz E; Weinzimer S; Tamborlane W
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1088-1094. PubMed ID: 29211871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
    Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C
    Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
    Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
    Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.
    Hassan K; Heptulla RA
    Pediatr Diabetes; 2009 Jun; 10(4):264-8. PubMed ID: 19140902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.
    Riddle MC; Yuen KC; de Bruin TW; Herrmann K; Xu J; Öhman P; Kolterman OG
    Diabetes Obes Metab; 2015 Sep; 17(9):904-7. PubMed ID: 26040429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.
    Woerle HJ; Albrecht M; Linke R; Zschau S; Neumann C; Nicolaus M; Gerich J; Göke B; Schirra J
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E103-9. PubMed ID: 17971511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.